Synonyms: AR-R15896AR | ARL 15896 | AZD-6765 | AZD6765
Compound class:
Synthetic organic
Comment: Lanicemine (AZD 6765) was originally developed as a neuroprotective agent, but was repurposed as an antidepressant with potential for the management of severe and treatment-resistant depression [3]. However, the compound failed to meet study endpoints, so development was halted. The compound is discussed in the AZ 2014 review paper [1].
The structure represented here shows stereochemistry identical to the INN record wheras PubChem CID 3038485 represents the non-chiral molecule. |
|
References |
1. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN. (2014)
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov, 13 (6): 419-31. [PMID:24833294] |
2. Monaghan DT, Larsen H. (1997)
NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology. J Pharmacol Exp Ther, 280 (2): 614-20. [PMID:9023271] |
3. Zarate Jr CA, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA. (2013)
A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry, 74 (4): 257-64. [PMID:23206319] |